Fluidigm Corporation (FLDM) skyrockets again from rumors of FDA Emergency Use Authorization

Fluidigm Corporation (FLDM) surges again from rumors of an FDA emergency use authorization granted to the company. Three weeks ago, Fluidigm Corporation was selected for a $37 million dollar project under National Institutes of Health RADx Initiative.

Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies.

With today’s gains, Fluidigm Corporation now has a market cap of $564.11 million. Shares of Fluidigm Corporation have been trading within a range of $9.27 and $1.17 over the last year, and it had a 50-day SMA and a 200-day SMA.

Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm’s revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.

Fluidigm Corporation is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.


Looking to beat the market?

Sign up and get Money Signals straight to your phone with over 50% in profits! Join now!

Default image
Tim Rolle
Investor of 6 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.
Articles: 113

Newsletter Updates

Enter your email address below to subscribe to our newsletter